Long-Term Outocomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Bristol-Myers K.K.
- 10 Jun 2017 Biomarkers information updated
- 20 Jun 2016 Planned End Date changed from 28 Feb 2023 to 1 Sep 2023.
- 20 Jun 2016 Status changed from not yet recruiting to recruiting.